This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark BMS's performance against key rivals in the ethical pharmaceutical sector See how the recently launched Atripla and Orencia will drive BMS's growth to 2012 Evaluate the prospects of BMS's leading thrombosis treatment Plavix, which will come under pressure from new competition and lose patent protection.